Jarushka Naidoo

What Attendees Can Expect from WCLC25 - IASLC - OncoDaily What Attendees Can Expect from WCLC25 - IASLC / cancer, IASLC, International Association for the Study of Lung Cancer, Isabelle Schmitt-Opitz, Jarushka

IASLC - What Attendees Can Expect from WCLC25
@iaslc.bsky.social
@stephenvliu.bsky.social
@narjustflorezmd.bsky.social
@drjnaidoo.bsky.social

oncodaily.com/blog/wclc25-...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #WCLC25 #IASLC

Jarushka Naidoo Shares Duncan Preece’s Patient-Focused Insights from ALK Positive Canada - OncoDaily Jarushka Naidoo Shares Duncan Preece’s Patient-Focused Insights from ALK Positive Canada / ALK Positive, cancer, Duncan Preece, Jarushka Naidoo, Lung Health

Jarushka Naidoo Shares Duncan Preece’s Patient-Focused Insights from ALK Positive Canada
@drjnaidoo.bsky.social

oncodaily.com/blog/jarushk...

#ALKPositive #Cancer #LungHealthCheckIreland #OncoDaily #Oncology

Clinical benefit and cost of plasma-first next-generation sequencing in patients with newly diagnosed advanced non-small cell lung cancer in Ireland: The PLAN study We report a pilot clinical trial investigating the feasibility of liquid biopsy genotyping (LBG) at the time of radiological suspicion of advanced NSCLC, incorporating a micro-cost model (MCM). (PLAsm...

Congrats #DavidOReilly
on the PLAN trial: plasma-first liquid biopsy (LB) v tissue (TB) for NSCLC in🇮🇪 @EJCancer
- 138pts
- 3wk⬇️ time to genomic result,LB>TB
- 90% concordance
- LB half the cost (micro-cost analysis)
@oncoalert.bsky.social @cancertrialsie.bsky.social
www.ejcancer.com/article/S095...

🎤 Meet @drjnaidoo.bsky.social , from Beaumont @rcsi.bsky.social  Cancer Centre (Dublin, Ireland) as a speaker at the Targeting RAS Symposium 2025.

Dr. Naidoo will give her talk during Session 5 on Day 2 at 09:25h. 

🔗 https://targetingras.com/registration/

#TargetingRAS2025 #25anniversaryCIC

YouTube video by European Society for Medical Oncology (ESMO) Diary of an oncology leader: Episode 1 – Solange Peters

What an inspiring video to wake up to!

🙌find strength in your team
🙌defend what is right
🙌you can do ANYTHING but not everything
🙌fight imposter syndrome - you deserve to be there

youtu.be/i6fe2EK2lh8?...

@solangepeters.bsky.social
@drjnaidoo.bsky.social

#ESMO #Women4Oncology #oncology

Photo of Dr Naidoo on stage

Dr Naidoo presenting conclusions

Compares future to various movies

Professor @drjnaidoo.bsky.social welcomed to the #BTOG25 stage as a Lung Cancer Legend & doesn’t disappoint. Lots of discussion on how we turn discussions on Small Cell Lung Cancer on its head. Lots of optimism in #SCLC coming from new standards & future treatments. #LCSM

Although @stephenvliu.bsky.social is hard to follow, we’ve just had an absolute tour de force by @drjnaidoo.bsky.social at #BTOG25 on #SCLC

➡️ Discusses NRG005 and the better outcomes for patients reviving twice daily radiotherapy.

➡️ Continued evidence of a benefit from PCI in LS-SCLC

With the successful role out of the TLHC programme, we now have a growing cohort of stage 1 SCLC patients. Hopefully this will become even more common, and work needed to understand optimal patient management @drjnaidoo.bsky.social #BTOG25

Agree. A packed room for SCLC on the last day of a conference? Unheard of previously! Obviously all attending to listen to @annaminchom.bsky.social , @drjnaidoo.bsky.social ,& @stephenvliu.bsky.social!

@btog.bsky.social #BTOG25

Fantastic over of #radiation induced pneumonitis by #ESTRO President @mguckenberger.bsky.social at #BTOG25

Updates the congress on the new #ESTRO guidelines in this area

@drjnaidoo.bsky.social @drpeedell.bsky.social

Long-Term Toxicity of Immune Checkpoint Inhibitors This Viewpoint discusses the need to quantify the long-term adverse effects of immune checkpoint inhibitors, particularly immune-related adverse effects, which are not universally dose dependent, limi...

Long-Term Toxicity of Immune Checkpoint Inhibitors @jama.com

Here, our stellar fellow #ChrisCronin charts a roadmap of how to quantitate the nuanced toxicities of IO from irAEs to time toxicity towards IO survivorship

#CancerCentreIre @oncoalert.bsky.social #LCSM
jamanetwork.com/journals/jam...

Discovery of BBO-8520, a First-In-Class Direct and Covalent Dual Inhibitor of GTP-Bound (ON) and GDP-Bound (OFF) KRASG12C Abstract. Approved inhibitors of KRASG12C prevent oncogenic activation by sequestering the inactive, GDP-bound (OFF) form rather than directly binding and inhibiting the active, GTP-bound (ON) form. T...

Interesting new compound in the KRAS world, BBO-8520 @theaacr.bsky.social
- First-In-Class inhibitor of KRAS G12Ci in GTP-Bound (ON)+GDP-Bound (OFF) states
- Ph I ONKORAS-101 trial ongoing, BBO-8520+\- pembro

@oncoalert.bsky.social @kraskickers.bsky.social #LCSM

aacrjournals.org/cancerdiscov...

IASLC #WCLC2025 is upon us! Your co-chairs cannot wait to welcome you #NoemiReguart 🇪🇸 #IsabelleOpitz🇨🇭 #UmbertoMalapelle 🇮🇹 & a familiar face from🇮🇪

Registration & abstract submissions are OPEN!

Join us in Barcelona | Sept 6–9, 2025 @iaslc.bsky.social @oncoalert.bsky.social #LCSM bit.ly/IASLCWCLC

Delighted to host @medsir.bsky.social today at #BeaumontRCSICancerCentre, exploring novel ways to develop & expand investigator initiated trials for cancer in Ireland 🇮🇪, through @cancertrialsie.bsky.social & beyond

Welcome @medsir.bsky.social

@rcsi.bsky.social #LCSM

Early detection of lung cancer showcased at #BeaumontHospital GP study day today by #DanielJRyan, ahead of the start of the Beaumont-RCSI-Irish Cancer Society Lung Health Check Pilot Trial, opening this year

#EuropeLung #ERS #LungAmbition #RCSI #LCSM

Are you a European clinician🇪🇺 who treats pts with IO & manages #irAEs? Join us in creating a pan-European vision for #irAE care🌍

Complete this short set of q’s on irAE care in your institution & country: vub.fra1.qualtrics.com/jfe/form/SV_...

@oncoalert.bsky.social

A privilege to be part of the ESMO Women for Oncology Committee!

A snapshot of members & the important themes fostered this year: community, leadership, support 🌍

Watch this space for new creative content & events in 2025 🏆 @elinardou.bsky.social @solangepeters.bsky.social

PCCM Fellow playing guitar for dying patient. shared with permission

IM resident playing guitar for dying patient. shared with permission.

Dying on Xmas day is always so hard on those who are left behind. There is little we can do to make that memory ok. Here, our #PCCM fellow and #IM resident went above & beyond to serenade a dying patient on #Christmas morning. #EOLcare @3wishesprogram.bsky.social

Dissection of Progressive Disease Patterns for a Modified Classification for Immunotherapy This study examines a modified progressive disease classification and its association with postprogression survival in patients treated with atezolizumab across various solid tumors.

Can patterns of progression on IO, inform future decisions?

-1377pts from 5 ph 3 trials used to create 3 PD risk levels
- low (⬆️existing lesions), intermediate (new lesions), high (both)
- risk score assoc w post-PD OS across tumors

Prognostic, so far #LCSM

jamanetwork.com/journals/jam...

It’s a good question

#ESMOImmuno24
Proffered paper🔥

Ph III CM73L: Nivo+cCRT➡️consol Nivo/Ipi v Nivo v cCRT➡️Durva @solangepeters.bsky.social

- no PFS/OS benefit
- g3+TRAE 57%, 54%, 49%
- concerning pneumonitis signal

Concurrent RT+IO - going going gone
@oncoalert.bsky.social #LCSM #Medsky #Oncsky

#ESMOImmuno24
Proffered paper🔥

Gut microbiome in Ph III NIPPON trial (N/I/chemo v Pembro/chemo 1L) #JCOG

- Fusicatenibacter, Butyricicoccus = ⬆️ OS (esp with N+I: HR 0.56, 0.52) & ⬇️severe irAEs
- Blautia = ⬆️OS
- Prevotella species = ⬇️OS with N+I

@oncoalert.bsky.social #MedSky #OncSky #LCSM

Phase 1/2 trial of XPO1 inhibitor selinexor plus docetaxel in previously treated, advanced KRAS mutant non-small cell lung cancer Abstract. Purpose: Patients with KRAS mutant non-small cell lung cancer (NSCLC) have limited therapeutic options. Based on activity of nuclear export inhibition in preclinical models, we evaluated thi...

Ph 1/2 trial selinexor+docetaxel in adv KRAS+ NSCLC @theaacr.bsky.social

- selinexor is a XPO1 inhibitor with activity in KRAS+ PDX models, p53 is neg predictor of response
- 40pts, MTD 60mg weekly
- ORR 80 v 27% KRAS+/p53WT v p53+

@oncoalert.bsky.social #LCSM

aacrjournals.org/clincancerre...

Can gender & genetics impact alectinib tox? @jtoonline.bsky.social

- 215pts with ALK+ NSCLC
- women had ⬆️g3+ tox (f v m: 56% v 34% p=0.001), 35% had ⬆️trough levels p<0.001
- Pts with SNP affecting alectinib metabolism (PPAR-α 209G>A) had ⬆️g3+ tox

#Medsky #Oncsky #LCSM

www.jto.org/article/S155...

Tables and Tornadoes: The Best Tools for the Job?

Tables (sometimes BIG) are among most routinely used tools to show data like baseline characteristics & AEs, while “tornado plots” are a standard figure to display AEs & sometimes other variables.

But could we do better, esp for live talks? (1/8)

FDA approves durvalumab for limited-stage small cell lung cancer On December 4, 2024, the Food and Drug Administration approved durvalumab (Imfinzi, AstraZeneca) for limited-stage small cell lung cancer (LS-SCLC).

FDA approves durvalumab for LS small cell lung cancer based on Ph III ADRIATIC trial:

- PFS benefit (HR 0.76)
- OS benefit (HR 0.73)
- 2 yrs durvalumab after definitive chemoRT
- currently available in 🇮🇪 on EAP

www.fda.gov/drugs/resour...

#MedSky #OncSky #LcSM @oncoalert.bsky.social

Lung cancer research and treatment: global perspectives and strategic calls to action Lung cancer remains a critical public health issue, presenting multifaceted challenges in prevention, diagnosis, and treatment. This article aims to r…

Great summary in @Annals_Oncology of an intensive few days in March 2024 discuss the key issues confronting lung cancer care globally, thanks to Dr. @mayluciemeyer for her excellent leadership on this manuscript! #lcsm @IASLC @myESMO
www.sciencedirect.com/science/arti...

a man with long hair and a beard is standing in the snow with mountains in the background . ALT: a man with long hair and a beard is standing in the snow with mountains in the background .

Now is the winter of our discontent

Richard III 1.1

#ShakespeareSunday #WinterTheme #GameofThrones

Management of severe immune-related adverse events and outcomes in patients with advanced non-small cell lung cancer receiving immune checkpoint inhibitors AbstractBackground. Immune checkpoint inhibitors (ICIs) are associated with severe immune-related adverse events (s-irAEs) that result in hospitalization,

Pleased to share our paper on the impact of severe irAEs in adv NSCLC #TheOncologist
- 3211pts, ConcertAI database
- 8.6% s-irAEs: diarrhea 3.5%, pneu 1.4%
- s-irAEs req steroids/immunosuppression=53%⬆️risk death v no irAE

@oncoalert.bsky.social #MedSky #OncSky #LCSM
academic.oup.com/oncolo/advan...

Phase II study of durvalumab + tremelimumab + chemotherapy in #EGFR NSCLC post TKI @jtoonline.bsky.social (n=100). In T790M- (including 1L osi), RR 31% (none in PDL1 negative), DOR 9.5m, PFS 6.5m. In T790M+ (with 2L osi), RR 21%, DOR 6.3m, PFS 4.9m. Modest activity.

www.jtocrr.org/article/S266...